Horizon scanning: Phase II study of FovistaTM and ranibizumab combination vs. ranibizumab monotherapy in wet AMD

Source: BioSpace
Area: News
Ophthotech Corporation has announced results from a prospective, randomised, controlled phase IIb trial of FovistaTM and ranibizumab combination therapy that show statistically significant superior efficacy over ranibizumab monotherapy for the treatment of neovascular age-related macular degeneration (wet AMD).   Fovista, formerly known as E10030, is an aptamer directed against platelet-derived growth factor subunit B (PDGF-B), which regulates neovascular pericytes (cells associated with the walls of newly formed small blood vessels).   In the study, 449 patients were randomised to receive one of the following treatment regimens (Read more...)

Full Story →